SEATTLE, June 4 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX)
announced today that Philip Laub has been promoted to vice president of
human resources.
"In his eight years at Immunex, Phil's accomplishments have helped us
achieve national recognition as one of the best companies to work for," said
Ed Fritzky, Immunex chairman, chief executive officer and president. "As we
continue to expand our workforce and number of locations, Phil's leadership
and advice will help us to successfully navigate the challenges of growth."
Prior to joining Immunex in 1993, Laub held human resources positions with
other leading organizations, such as Syntex Labs, Charles Schwab and
Wells Fargo Bank. He holds a bachelor of science degree in organizational
behavior from the University of San Francisco. Laub succeeds Kathy Spencer,
who will serve in advisory capacity with Immunex.
Immunex Corporation is a leading biopharmaceutical company dedicated to
improving lives through immune system science innovations.
NOTE: Except for the historical information contained herein, this news
release contains forward-looking statements that involve substantial risks and
uncertainties. Among the factors that could cause actual results or timelines
to differ materially are risks associated with research and clinical
development, regulatory approvals, our supply capabilities and reliance on
third-party manufacturers, product commercialization, competition, litigation
and other risk factors listed from time to time in reports filed by Immunex
with the SEC, including but not limited to risks described under the caption
"Important Factors That May Affect Our Business, Our Results of Operations and
Our Stock Price" within our most recently filed Form 10-Q. The
forward-looking statements contained in this news release represent our
judgment as of the date of this release. Immunex undertakes no obligation to
publicly update any forward-looking statements. An electronic version of this
news release -- as well as additional information about Immunex of interest to
investors, customers, future employees and patients -- is available on the
Immunex home page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
media, Kris Greco, 206-470-4871, or
investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
